Nautilus Biotechnology Reports $14.7 Million Net Loss in Q1 2026, Seeks Additional Funding

Nautilus Biotechnology, Inc. reported a net loss of $14.7 million for the first quarter of 2026, a decrease from the $16.6 million loss recorded in the same period of the previous year. The company's total operating expenses for the quarter were $16.1 million, down 14% from $18.8 million in Q1 2025. This reduction was primarily driven by lower research and development costs, which fell to $9.7 million from $11.5 million, reflecting savings from workforce reductions implemented in early 2025. Selling, general, and administrative expenses also decreased by 12% to $6.4 million, attributed to reduced stock-based compensation and personnel costs.

As of March 31, 2026, Nautilus held cash, cash equivalents, and short-term investments totaling $95.9 million, a slight decrease from $106 million at the end of 2025. The company’s accumulated deficit increased to $346.7 million, highlighting the ongoing financial challenges as it continues to invest heavily in the development of its Nautilus Voyager™ platform, which remains in the development stage. The company has not yet generated any revenue from product sales since its inception.

In terms of operational developments, Nautilus has initiated its Early Access Program, which began in January 2026, focusing on the analysis of the microtubule-associated protein tau, linked to Alzheimer’s disease. This program is part of a phased commercialization strategy that aims to establish research collaborations with biopharmaceutical companies and academic institutions. The company plans to expand its offerings to include additional proteoforms and expects to launch its Nautilus Voyager platform for pre-orders in late 2026, with installations beginning in early 2027.

Nautilus has also made strategic moves to enhance its operational capabilities, including the hiring of its first sales personnel to build an internal sales infrastructure. The company is focused on establishing its commercial organization and distribution capabilities, with plans to expand into international markets, including the European Union and Asia-Pacific regions. However, the company acknowledges that it will require substantial additional funding to support its ongoing research and development activities, as well as to establish sales and marketing capabilities.

Looking ahead, Nautilus anticipates continued significant losses as it progresses with its commercialization efforts. The company has indicated that it may need to seek additional financing to support its operations and development plans, which could include public or private equity offerings. The future capital requirements will depend on various factors, including the pace of product development and market conditions. The company remains cautious about its financial outlook, given the uncertainties in the global economic environment and the competitive landscape in the biotechnology sector.